Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
Authors
Keywords
-
Journal
JAMA Internal Medicine
Volume 182, Issue 12, Pages 1278
Publisher
American Medical Association (AMA)
Online
2022-11-08
DOI
10.1001/jamainternmed.2022.5010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
- (2022) Paul A. Heidenreich et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
- (2022) Muthiah Vaduganathan et al. LANCET
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review
- (2021) Hannah Clark et al. HEART FAILURE REVIEWS
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
- (2021) Justin T. Parizo et al. JAMA Cardiology
- Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
- (2021) Javed Butler et al. CIRCULATION
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
- (2021) Michael E. Nassif et al. NATURE MEDICINE
- Health Status and Cardiac Rehabilitation—Putting a Dollar Amount on Improvement
- (2021) Paul A. Heidenreich JAMA Cardiology
- Change of Health‐Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure
- (2020) Nariman Sepehrvand et al. Journal of the American Heart Association
- Epidemiologic Characterization of Heart Failure with Reduced or Preserved Ejection Fraction Populations Identified Using Medicare Claims
- (2020) Rishi J. Desai et al. AMERICAN JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction
- (2019) Jonathan Yap et al. Journal of the American Heart Association
- Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction
- (2019) Jasper Tromp et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Patient-Reported Outcomes
- (2019) Paul A. Heidenreich JACC-Heart Failure
- Health Care Utilization and Burden of Diabetic Ketoacidosis in the U.S. Over the Past Decade: A Nationwide Analysis
- (2018) Dimpi Desai et al. DIABETES CARE
- Identifying Subgroups of Adult Superutilizers in an Urban Safety-Net System Using Latent Class Analysis
- (2018) Deborah J. Rinehart et al. MEDICAL CARE
- Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
- (2017) John J V McMurray et al. HEART
- Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction
- (2017) Kevin S. Shah et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Unknown
- (2016) EUROPEAN JOURNAL OF HEART FAILURE
- Utility of Patient-Reported Outcome Instruments in Heart Failure
- (2016) Anita A. Kelkar et al. JACC-Heart Failure
- Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
- (2016) Thomas A. Gaziano et al. JAMA Cardiology
- Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
- (2015) Jenny Berg et al. VALUE IN HEALTH
- A Reevaluation of the Costs of Heart Failure and Its Implications for Allocation of Health Resources in the United States
- (2014) Jeff Voigt et al. CLINICAL CARDIOLOGY
- The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective
- (2014) A Griffiths et al. HEART
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction
- (2013) Susan M. Joseph et al. Circulation-Heart Failure
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- In-Hospital Resource Use and Medical Costs in the Last Year of Life by Mode of Death (from the HF-ACTION Randomized Controlled Trial)
- (2012) Shelby D. Reed et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lifetime Costs of Medical Care After Heart Failure Diagnosis
- (2010) Shannon M. Dunlay et al.
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now